From National Institutes of Health Web Sites
- Approval of Osimertinib and Necitumumab Increases Lung Cancer Treatment Options
- Bringing Precision to Screening for Cancer
- Enhanced Risk-Based Lung Cancer Screening May Prevent More Deaths than Current Approaches
- FDA Approves Alectinib for ALK-Positive Non-Small Cell Lung Cancer
- Most cases of lung cancer are due to smoking; however, there are other risk factors including family history.
- Noninvasive strategies for lung cancer testing
NIH Research Matters, March 7, 2017 - Targeted Photoimmunotherapy Approach for Cancer Moves Forward
- Two-Drug Combination Approved for Lung Cancers with BRAF Mutations
NCI, July 18, 2017 - Using Gene Expression to Diagnose Lung Cancer More Accurately
- With FDA Approval, Gefitinib Returns to U.S. Market for Some Patients with Lung Cancer
.png)
No hay comentarios:
Publicar un comentario